One in Four Patients Die Within One Year of First Heart Failure Hospitalization
30 Jun 2023
AHA
FRIDAY, June 30, 2023 -- Globally, one in four heart failure patients die within the first year of their first heart failure-related hospitalization, according to a study published online June 21 in JACC: Heart Failure.
Biykem Bozkurt, M.D., Ph.D., from Baylor College of Medicine in Houston, and colleagues described rehospitalizations, hospitalization costs, use of guideline-directed medical therapy, and mortality after hospitalization for heart failure. Analysis included electronic health record or claims data for 263,525 adult patients in Japan, Sweden, the United Kingdom, and the United States with a first heart failure discharge between 2018 and 2022.
The researchers found that 28 percent of patients died within the first year posthospitalization heart failure (event rate: 28.4). Heart failure (event rate: 13.6) and chronic kidney disease (CKD; event rate: 4.5) drove rehospitalizations. Similarly, heart failure and CKD drove health care costs. There was little change seen between 2020 and 2022 for use of renin-angiotensin system inhibitorsrenin-angiotensin system inhibitors, sacubitril/valsartan, beta-blockers, and mineralocorticoid receptor antagonists. However, uptake of sodium-glucose cotransporter-2 inhibitorssodium-glucose cotransporter-2 inhibitors increased two- to sevenfold.
"Incident posthospitalization heart failure rehospitalization risks and costs were high, and guideline-directed medical therapy use changed little in the year following discharge, highlighting the need to consider earlier and greater implementation of guideline-directed medical therapy to manage risks and reduce costs," the authors write.
Several authors disclosed ties to the pharmaceutical industry. Medical writing support was provided by AstraZeneca, which also funds EVOLUTION HF, the longitudinal cohort study from where the data was pulled.
Abstract/Full Text
Posted June 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.